|
CooperVision Strengthens Global Footprint with Expanded Access to Myopia Management in Asia-Pacific
ROCHESTER, N.Y., Feb. 10, 2026 /PRNewswire/ -- CooperVision today announced immediate availability of its MiSight® 1 day* myopia control contact lens in Japan, where as many as 77% of elementary school children are estimated to be myopic, equating to millions who could benefit from myopia control treatments.1 The country represents approximately 12% of the global contact lens marketplace.2
MiSight® 1 day is the first soft contact lens authorized by Japan's Ministry of Health, Labor and Welfare for use by children to correct myopia and control its progression.†‡3
"This milestone underscores CooperVision's deep commitment to improving the lives of children around the world with myopia by expanding access to proven solutions," said Jennifer Lambert, Vice President, Myopia Management and Cornea Care, CooperVision. "The launch of MiSight® 1 day in Japan represents an enormous step forward in that mission. Partnering with Japan's revered ophthalmology community, we are helping young patients see clearly today while protecting their vision for the future."
Myopia affects nearly one in three children worldwide and is expected to rise dramatically over the next few years.§4,5 By 2050, it's predicted that nearly five billion people will be myopic, with nearly one billion expected to have high levels of myopia.6 Also known as nearsightedness, myopia can significantly impact a child's quality of life—making it harder to participate in school, sports, and other activities.7,8 Myopia can also worsen rapidly, especially in younger children, so early intervention is important.9
MiSight® 1 day is approved for myopia control in more than 40 countries around the world, and is the first and only soft contact lens approved for myopia control in Japan, the United States and China.†**††‡‡§§3,10 Worldwide, children wearing MiSight® 1 day contact lenses collectively account for more than half a billion hours annually.***11
Featuring CooperVision's proprietary ActivControl® Technology—alternating correction and treatment zones that correct vision while creating myopia defocus to help slow myopia growth—the lenses have demonstrated an average 59% reduction in myopia progression after three years with 41% of eyes having no progression.†††3,10
"This is another significant step forward in our mission to take on myopia at a global scale," said Debbie Olive, Chief Commercial Officer, CooperVision. "For children and families affected, myopia can impact more than vision—it can influence daily life, learning, and long‑term potential. Expanding access to proven myopia control solutions means families don't have to face these challenges alone in Japan or other communities around the world."
MiSight® 1 day is part of CooperVision's comprehensive portfolio of myopia control and management solutions—the world's largest evidence-based range of interventions. This includes daytime soft contact lenses, spectacles and overnight orthokeratology lenses, designed to meet the diverse needs and lifestyles of children with myopia. Last month, the company announced availability of its MyDay® MiSight® 1 day contact lenses in the United Kingdom plus select European and surrounding markets, further extending its portfolio and category leadership.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
* Please consult your eyecare professional before using contact lenses.
† Intended purpose (purpose or effect of use): Correction and slowing the progression of nearsightedness.
‡ Compared to a single vision 1-day lens over a 24-month period.
§ Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
** China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternating multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.
†† U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal
‡‡ Compared to a single vision 1-day lens over a 3-year period.
§§ Intended purpose (purpose or effect of use): Correction and slowing the progression of nearsightedness.
*** Based on actual wearing hours as reported by study participants, plus estimated wearing hours for current total real-world wearers, assuming compliance with wearing times as per the indication.
††† Compared to single vision lens, no clinically meaningful change in refractive error (-0.25D or less from baseline). Fitted at 8-12 years of age.
1 Yotsukura E et al. Current prevalence of myopia and association of myopia with environmental factors among school children in Japan. JAMA Ophthalmol. 2019; 137(11): 1233-9.
2 Contact Lens Institute data, Q3 2025.
3 CVI data on file, 2025.
4 Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis
British Journal of Ophthalmology 2025;109:362-371.
5 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
6 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
7 E. L. Lamoureux et al. Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). IOVS 2008;49(13):4469.
8 Chua S.Y.L., Foster P.J. (2020) The Economic and Societal Impact of Myopia and High Myopia:53-63. In: Ang M., Wong T. (eds) Updates on Myopia. Springer, Singapore.
9 K. Zadnik et al. Factors Associated with Rapid Myopia Progression in School-aged Children. IOVS 2004;45(13):2306.
10 Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. OVS 2019 Aug;96(8):556-567.
11 CVI data on file 2025. Internal global wearer modeling estimates for the 12-month period of October 2024 to September 2025.
CooperVision Strengthens Global Footprint with Expanded Access to Myopia Management in Asia-Pacific
ROCHESTER, N.Y., Feb. 10, 2026 /PRNewswire/ -- CooperVision today announced immediate availability of its MiSight® 1 day* myopia control contact lens in Japan, where as many as 77% of elementary school children are estimated to be myopic, equating to millions who could benefit from myopia control treatments.1 The country represents approximately 12% of the global contact lens marketplace.2
MiSight® 1 day is the first soft contact lens authorized by Japan's Ministry of Health, Labor and Welfare for use by children to correct myopia and control its progression.†‡3
"This milestone underscores CooperVision's deep commitment to improving the lives of children around the world with myopia by expanding access to proven solutions," said Jennifer Lambert, Vice President, Myopia Management and Cornea Care, CooperVision. "The launch of MiSight® 1 day in Japan represents an enormous step forward in that mission. Partnering with Japan's revered ophthalmology community, we are helping young patients see clearly today while protecting their vision for the future."
Myopia affects nearly one in three children worldwide and is expected to rise dramatically over the next few years.§4,5 By 2050, it's predicted that nearly five billion people will be myopic, with nearly one billion expected to have high levels of myopia.6 Also known as nearsightedness, myopia can significantly impact a child's quality of life—making it harder to participate in school, sports, and other activities.7,8 Myopia can also worsen rapidly, especially in younger children, so early intervention is important.9
MiSight® 1 day is approved for myopia control in more than 40 countries around the world, and is the first and only soft contact lens approved for myopia control in Japan, the United States and China.†**††‡‡§§3,10 Worldwide, children wearing MiSight® 1 day contact lenses collectively account for more than half a billion hours annually.***11
Featuring CooperVision's proprietary ActivControl® Technology—alternating correction and treatment zones that correct vision while creating myopia defocus to help slow myopia growth—the lenses have demonstrated an average 59% reduction in myopia progression after three years with 41% of eyes having no progression.†††3,10
"This is another significant step forward in our mission to take on myopia at a global scale," said Debbie Olive, Chief Commercial Officer, CooperVision. "For children and families affected, myopia can impact more than vision—it can influence daily life, learning, and long‑term potential. Expanding access to proven myopia control solutions means families don't have to face these challenges alone in Japan or other communities around the world."
MiSight® 1 day is part of CooperVision's comprehensive portfolio of myopia control and management solutions—the world's largest evidence-based range of interventions. This includes daytime soft contact lenses, spectacles and overnight orthokeratology lenses, designed to meet the diverse needs and lifestyles of children with myopia. Last month, the company announced availability of its MyDay® MiSight® 1 day contact lenses in the United Kingdom plus select European and surrounding markets, further extending its portfolio and category leadership.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
* Please consult your eyecare professional before using contact lenses.
† Intended purpose (purpose or effect of use): Correction and slowing the progression of nearsightedness.
‡ Compared to a single vision 1-day lens over a 24-month period.
§ Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
** China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternating multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.
†† U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal
‡‡ Compared to a single vision 1-day lens over a 3-year period.
§§ Intended purpose (purpose or effect of use): Correction and slowing the progression of nearsightedness.
*** Based on actual wearing hours as reported by study participants, plus estimated wearing hours for current total real-world wearers, assuming compliance with wearing times as per the indication.
††† Compared to single vision lens, no clinically meaningful change in refractive error (-0.25D or less from baseline). Fitted at 8-12 years of age.
1 Yotsukura E et al. Current prevalence of myopia and association of myopia with environmental factors among school children in Japan. JAMA Ophthalmol. 2019; 137(11): 1233-9.
2 Contact Lens Institute data, Q3 2025.
3 CVI data on file, 2025.
4 Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis
British Journal of Ophthalmology 2025;109:362-371.
5 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
6 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
7 E. L. Lamoureux et al. Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). IOVS 2008;49(13):4469.
8 Chua S.Y.L., Foster P.J. (2020) The Economic and Societal Impact of Myopia and High Myopia:53-63. In: Ang M., Wong T. (eds) Updates on Myopia. Springer, Singapore.
9 K. Zadnik et al. Factors Associated with Rapid Myopia Progression in School-aged Children. IOVS 2004;45(13):2306.
10 Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. OVS 2019 Aug;96(8):556-567.
11 CVI data on file 2025. Internal global wearer modeling estimates for the 12-month period of October 2024 to September 2025.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CooperVision Launches MiSight® 1 day in Japan; Becomes First Myopia Control Contact Lens in Leading Vision Care Market
The fusion of AI-native storage and computing overcomes the final barrier to enterprise AI adoption, delivering unprecedented mobility, performance, and simplicity for data-sensitive industries.
SINGAPORE, Feb. 10, 2026 /PRNewswire/ -- Ridger, the world's pioneering AI-Native storage provider, today announced the successful completion of full compatibility certification between its flagship MIMO storage system and xFusion's FusionXpark™ Portable Agent Development Platform, powered by the NVIDIA GB10 (Grace Blackwell) superchip. This milestone delivers the industry's first truly integrated, portable AI infrastructure solution, effectively turning the promise of private, desktop-scale supercomputing into a practical reality for businesses worldwide.
From Data Center Chains to Portable Power: Solving the "Last-Mile" AI Dilemma
Global industries bound by strict data governance—including healthcare, legal, financial services, and creative sectors—face a critical challenge: harnessing the power of AI while ensuring data never leaves their secure premises. Traditional approaches force a compromise, tethering powerful AI to immobile, complex, and costly data center infrastructure. This has created a widespread "last-mile" gap, where AI is technically deployable but practically unusable due to logistical and operational burdens.
The "Fast, Light, Edge" Alliance: A Complete Stack in a Mobile Form Factor
The Ridger-xFusion partnership bridges this gap by uniting two purpose-built, best-of-breed platforms. Ridger MIMO, the cornerstone of AI infrastructure, delivers data center-class performance—400 GB/s bandwidth, 500M IOPS, and near 2PB capacity in a compact chassis—with an architecture fundamentally redesigned for AI workloads. Its native support for GPU storage protocols allows seamless, direct attachment of up to 16 FusionXpark™ units without additional switches.
xFusion FusionXpark™ leverages the revolutionary efficiency of the NVIDIA GB10 superchip (TSMC 3nm) to place 1 PFLOPS of FP4 AI computing power on the desktop, coupled with an integrated ecosystem and marketplace for instant deployment of AI agents and applications.
Together, they converge into a synergistic, mobile powerhouse that consolidates the entire AI workflow—from data preparation and model training to fine-tuning and real-time inference—into a single, elegantly simple, and highly portable deployment unit.
The New Architecture: Redefining Efficiency for Private AI
Third-party validated benchmarks and architectural analysis confirm the solution delivers not just incremental gains, but a fundamental shift in private AI infrastructure.
The Foundation: Storage That Fully Saturates Compute
MIMO's extreme, AI-native bandwidth is architected to fully saturate the dual QSFP interfaces of every FusionXpark™ unit. This ensures zero computational cycles are wasted waiting for data, transforming FusionXpark™'s 1 PFLOPS of FP4 power from a theoretical peak into guaranteed, sustained workload performance. It eliminates the I/O bottleneck at its root, ensuring every investment in compute silicon delivers its maximum return.
The System Impact: Unleashing Cluster-Wide Efficiency
This foundational data velocity creates a cascade of system-level advantages. With MIMO as a central, ultra-high-bandwidth data nexus, multiple FusionXpark™ nodes operate as a single, cohesive AI supercomputer. The shared storage pool eliminates data silos and replication overhead, enabling dynamic workload orchestration across the entire cluster for both training and inference. The result is a transformative increase in total usable compute output per dollar—maximizing the return on the entire AI investment.
The User Experience: Data-Center Performance, Desktop Deployment
This immense power is delivered in a form factor engineered for the edge. MIMO is not only compact and devoid of external switch dependencies but also incorporates a near-silent acoustic profile. It brings unprecedented data-center-grade performance directly to where data resides and decisions are made—in labs, offices, or field sites—without the noise, complexity, or infrastructure overhead of traditional equipment, eliminating the traditional trade-offs and fully delivering on the "Light and Edge" promise.
Executive Commentary
Bruce Xue, Spokesperson of Ridger: "Today marks the end of the 'unusable AI' era for regulated industries. By fusing true AI-native storage with accessible supercomputing, we've eliminated the last excuse for not deploying AI privately. The MIMO-FusionXpark™ solution isn't just another product; it's the first 'AI Appliance' for the edge—delivering cloud-scale performance with uncompromising data sovereignty. We're not just solving a storage problem; we're unlocking a trillion dollars of trapped data value."
Vandia Yang, Spokesperson of xFusion: "The future of AI isn't in the cloud; it's wherever your data lives. Our partnership with Ridger crystallizes this vision. Together, we've built what was previously impossible: a sovereign AI supercomputer that fits under a desk. This certification proves that performance and privacy are no longer a trade-off. We are giving every research lab, every hospital, every financial firm the keys to their own intelligence revolution."
Path to Deployment and Strategic Vision
The certified MIMO-FusionXpark™ integrated solution is available for order now through Ridger's official website and authorized partners, with shipments commencing at the end of February 2026.
This partnership, anchored by the NVIDIA GB10 platform, delivers a definitive blueprint for the future of private AI: a practical, closed-loop ecosystem of compute, storage, and intelligence that is as portable as it is powerful. Ridger remains committed to advancing this "Fast, Light, Edge" paradigm through continued R&D and ecosystem collaboration, driving the next wave of secure and sovereign AI adoption that is liberated from fixed infrastructure.
About Ridger
Ridger is defining the future of data infrastructure as the world's first AI-Native storage provider. Its flagship product, MIMO, is built on a ground-up architecture designed to unlock the full potential of AI and accelerated computing, prioritizing unparalleled speed, density, and edge readiness. Learn more at https://ridger.tech.
About xFusion
xFusion is a leading provider of computing infrastructure solutions. Its FusionXpark™ is a portable Agent Development Platform built on the NVIDIA GB10 superchip, bringing datacenter-scale AI performance to the edge and private environments. With its integrated AI agent marketplace and development tools, FusionXpark™ simplifies and accelerates the deployment of enterprise AI applications. Learn more at https://www.xfusion.com/en/product/fusionxpark?utm_source=homepage.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ridger Achieves xFusion's FusionXpark™ (NVIDIA GB10-Based) Compatibility Certification, Delivering Industry-Leading Mobility for Practical AI Deployment
